Bio-Rad Laboratories Inc. (BIO) exhibits 51.9% gross margins and 0.5% return on invested capital within Health Care (Biotechnology: Laboratory Analytical Instruments), balanced against a 60.4x enterprise multiple and 4.8% implied options volatility.
Sustained 51.9% gross profitability converts into 1.8% operating margin and 0.5% ROIC, outpacing sector cost of capital.
ROIC: 0.5% // GM: 51.9%YoY revenue trajectory of +0.7% paired with 3.64% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +0.7% // FCF YLD: 3.64%Altman Z-Score of 3.59 and Piotroski F-Score of 7/9 indicate low near-term refinancing stress.
ALTMAN Z: 3.59 // F-SCORE: 7/9Trading at 13.5x trailing P/E (12.6x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 13.5x // EV/EBITDA: 60.4xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $366.16 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Laboratory Analytical Instruments require continuous execution to defend 29.4% net margins.
NET MARGIN: 29.4% // D/E: 0.16x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for BIO & activate live FRED threshold breach alerts.